Oxidative/antioxidative status, lymphocyte DNA damage, and urotensin-2 receptor level in patients with migraine attacks

Figures & data

Figure 1 DNA damage in human lymphocytes assessed with alkaline comet assay.

Note: Photomicrographs of comet classes (Class 0: undamaged to Class 4: maximally damaged).

Figure 2 Plasma concentrations of markers of lymphocyte DNA damage in migraine patient groups categorized according to MIDAS score.

Notes: MIDAS-II, mild disability, (score, 6–10); MIDAS-III, moderate disability, (score, 11–20); MIDAS-IV, severe disability, (score, >20).
Abbreviation: MIDAS, Migraine Disability Assessment Scale.

Figure 3 Plasma concentrations of CAT in migraine patient groups categorized according to MIDAS score.

Abbreviations: CAT, catalase; MIDAS, Migraine Disability Assessment Scale.

Table 1 Demographic data and plasma measures of 40 adult patients with migraine and 40 healthy controls

Characteristics	Control group n=40	Patients with migraine n=40	P-value
Age (years)	33.30+9.40	33.20+9.38	0.953
Sex (female/male)	24/16	26/14	0.768
UTS2R (ng/mL)	28.15±11.20	11.16±4.86	<0.001
CAT (IU/mL)	0.73±0.17	0.44±0.18	<0.001
TAS (mmol Trolox^® equiv./L)	2.29±1.30	1.18±0.68	<0.001
TOS (μmol H2O2 equiv./L)	34.45±9.08	44.75±16.74	0.007
OSI (AU)	1.70±0.60	4.43±2.29	<0.001
MDA (nmol/L)	0.59±0.07	0.78±0.09	<0.001
DNA damage (arbitrary units)	23.81±10.15	43.51±13.93	<0.001

Notes: Data are presented as mean ± SD or n. Inter-group comparisons (controls vs patients) were analyzed by chi-square and Mann–Whitney U tests where appropriate.

Abbreviations: CAT, catalase; MDA, malondialdehyde; n, numbers of patients; OSI, oxidative stress index; SD, standard deviation; TOS, total oxidant status; TAS, total antioxidant status; Trolox^®, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; UTS2R, urotensin 2 receptor.

Table 2 Comparisons of plasma measures in 40 adult patients classified according to severity of migraine using the MIDAS score

Characteristics	MIDAS-II group n=8	MIDAS-III group n=17	MIDAS-IV group n=15	P-value
UTS2R (ng/mL)	10.56±2.14	10.09±4.00	12.70±6.41	0.401
CAT (IU/mL)	0.35±0.19	0.53±0.19	0.38±0.12	0.040
TAS (mmol Trolox^® equiv./L)	1.37±1.33	1.14±0.42	1.13±0.43	0.773
TOS (μmol H2O2 equiv./L)	45.41±18.18	46.46±13.51	42.48±19.94	0.504
OSI (AU)	4.34±2.37	4.55±1.90	4.35±2.77	0.792
MDA (nmol/L)	0.79±0.08	0.79±0.10	0.77±0.09	0.841
DNA damage (arbitrary units)	24.48±6.06	45.02±10.15	51.95±10.88	<0.001

Notes: Data are presented as mean ± SD or n. Intra-group comparisons (MIDAS groups) were analyzed by the one-way analysis of variance test. MIDAS-II, mild disability, (score, 6–10); MIDAS-III, moderate disability, (score, 11–20); MIDAS-IV, severe disability, (score, >20).

Abbreviations: CAT, catalase; MDA, malondialdehyde; MIDAS, Migraine Disability Assessment Scale; n, numbers of patients; OSI, oxidative stress index; TAS, total antioxidant status; TOS, total oxidant status; Trolox^®, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; UTS2R, urotensin 2 receptor.